<DOC>
	<DOCNO>NCT03059888</DOCNO>
	<brief_summary>This pilot research study do see drug abatacept ( Orencia Â® ) helpful treat patient myasthenia gravis ( MG ) respond satisfactorily drug use suppress immune system . Abatacept successful treat experimental MG laboratory animal , study determine effectiveness patient MG .</brief_summary>
	<brief_title>Trial Orencia Patients With Myasthenia Gravis</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Able comprehend willing sign Informed Consent Form ( ICF ) Male female 16 85 year age Diagnosis DEFINITE Myasthenia Gravis History inadequate response conventional MG treatment Clinical laboratory finding within normal range , outside normal range , deem clinically significant Investigator Female patient childbearing potential breastfeeding , negative pregnancy test , intention become pregnant course study , use contraceptive drug device prevent pregnancy participation study Willing cooperate study requirement , include visit study site every 2 month . Subject 's MG respond adequately conventional immunosuppressive treatment Subject previous trial immunosuppressive agent Subject history Chronic Obstructive Pulmonary Disease ( COPD ) Subject impair , incapacitate incapable completing studyrelated assessment Subject presence screening severe , progressive uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurologic cerebral disease , whether related MG , opinion Investigator , might place subject unacceptable risk participation study . Female subject history breast cancer screen suspicious malignancy possibility malignancy reasonably exclude additional clinical , laboratory diagnostic evaluation Subject history cancer last 5 year , nonmelanoma skin cell cancer cure local resection carcinoma situ Subject currently abuse drug alcohol Subject evidence active latent bacterial viral infection , include positive infectious disease laboratory test result ( Hepatitis B , Hepatitis C HIV ) Subject history herpes zoster cytomegalovirus ( CMV ) infection resolve less 2 month prior screen visit Subject receive live vaccine within 3 month screen Subject history serious bacterial infection within last 3 month , unless treat resolved antibiotic ; , chronic bacterial infection Subject risk tuberculosis Subject follow laboratory value : Hemoglobin &lt; 8.5 g/dL ; White Blood Cells ( WBC ) &lt; 3000 mm3 ; Platelets &lt; 100,000 mm3 ; Serum creatinine &gt; 2x upper limit normal ( ULN ) ; Serum Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &gt; 2x ULN Subject unable unwilling maintain weekly injection schedule Subject undergone change immunosuppressive medication within last three month prior enrollment . Subject neurological impairment due condition MG , include history transient ischemic attack within past year Subject take investigational study drug within 28 day five halflives prior agent , whichever great , prior dose Subject previous exposure Orencia ( abatacept ) Subject prisoner involuntarily incarcerate Subject compulsorily detain treatment either psychiatric physical illness Subject judge actively suicidal suicide risk Investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>